Brian Abel-Smith Professor of Health Policy and Head of Department
London School of Economics
Elias Mossialos is Brian Abel-Smith Professor of Health Policy and Head of Department in the Department of Health Policy at LSE. He is also Professor in Health Policy and Management, Director of LSE Health, and Co-Director of the European Observatory on Health Systems and Policies and the Centre for Health Policy at Imperial College London. He is associate editor of the Health Systems and Reform and European Heart Journal – Quality of Care & Clinical Outcomes. In 1995, he founded Eurohealth, a quarterly journal bridging academic scholarship and policy-making, and since 1998 he has been the Editor-in-Chief of the Health Systems in Transition reviews, published by the WHO.
Professor Mossialos founded LSE Health in 1996, currently LSE's largest research centre with 60 staff working on a wide range of research, combining technical competence with policy-mindedness. The Centre fosters the training of young researchers and funds several doctoral and post-doctoral students: the Centre has contributed more than £1.5 million of its own funds to support its PhD students.
Professor Mossialos established the MSc in International Health Policy at LSE in 1999, which attracted high quality students from more than 90 countries, and in 2009, a modular MSc in Health Economics, Policy and Management directed at mid-career professionals who lack the flexibility to participate in a traditional MSc programme. In 2014, in collaboration with the European Society of Cardiology, he established a modular MSc in Health Economics, Outcomes and Management. In 2014, he established an interdisciplinary MSc in Global Health, and in 2018 he will launch an executive Master’s programme in Global Health Policy in co-operation with the University of Chicago.
Professor Mossialos’ research focus is comparative health systems and policy, addressing questions related to health reforms, financing health care, pharmaceutical policies, the impact of EU law on health care systems, cancer care, and policy and antibiotics. He is currently analysing incentives to address the need for sufficient investment in the development of antibiotics in order to meet changing medical needs.
He has advised the WHO, European Parliament, European Commission (EC), World Bank, UK Office of Fair Trading, Ministries of Health and Social Affairs in Belgium, Brazil, China, Cyprus, Finland, Greece, Ireland, Kazakhstan, Russia, Slovenia, South Africa, Spain and Sweden, and health insurance funds in Austria, Croatia, France, Hungary and South Korea. He was a member of the management board of the European Medicines Agency (2000-2003) and the board of the Hellenic National Medicines Agency (2000-2002) and contributed to the International Forum on 'Common access to health care services' co-ordinated by the health ministers of Sweden, the UK and New Zealand.